Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 13/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.46 |
| ▸ | CDK2 | P24941 | 6/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.46 |
| ▸ | CDK4 | P11802 | 4/20 | 0.46 |
| ▸ | CCND1 | P24385 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6999184 | 0.91 | PDE2A (0.57) | PDE2ACCNE1CDK2CCNE2CDK4 | |
| SCHEMBL6987648 | 0.90 | PDE2A (0.47) | PDE2ACCNE1CDK2CCNE2CDK4 | |
| SCHEMBL6992393 | 0.88 | PDE2A (0.55) | PDE2ACCNE1CDK2CCNE2CDK4 | |
| SCHEMBL6996492 | 0.88 | PDE2A (0.47) | PDE2ACCNE1CDK2CCNE2CDK4 | |
| SCHEMBL7000731 | 0.86 | PDE2A (0.57) | PDE2APOLB | |
| SCHEMBL7354927 | 0.86 | PDE2A (0.57) | PDE2ACCNE1CDK2CCNE2CDK4 | |
| SCHEMBL6991709 | 0.86 | PDE2A (0.58) | PDE2ACCNE1CDK2CCNE2CDK4 | |
| SCHEMBL6991547 | 0.85 | PDE2A (0.49) | PDE2ACCNE1CDK2CCNE2CDK4 | |
| SCHEMBL6998591 | 0.85 | PDE2A (0.45) | PDE2APOLB | |
| SCHEMBL6997188 | 0.80 | CCNE2 (0.52) | PDE2ACCNE1CDK2CCNE2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229242-A1 | Composition comprising a pulmonary surfactant and a pde2 inhibitor | ALTANA PHAZMA AG (DE) | 2006-10-12 | — | — | US | claimed |
| EP-1660132-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE2 INHIBITOR | ALTANA Pharma AG (DE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005021037-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE2 INHIBITOR | ALTANA PHARMA AG (DE) | 2005-03-10 | — | — | WO | claimed |
| EP-1697356-B1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | PFIZER PROD INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PFIZER INC. | 2007-06-14 | — | — | US | disclosed |
| US-20060229242-A1 | Composition comprising a pulmonary surfactant and a pde2 inhibitor | ALTANA PHAZMA AG (DE) | 2006-10-12 | — | — | US | disclosed |
| EP-1660132-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE2 INHIBITOR | ALTANA Pharma AG (DE) | 2006-05-31 | — | — | EP | disclosed |
| US-7022709-B2 | Selective PDE 2 inhibitors as pharmaceuticals for improving perception | BAYER AKTIENGESELLSCHAFT (DE) | 2006-04-04 | — | — | US | disclosed |
| WO-2005021037-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE2 INHIBITOR | ALTANA PHARMA AG (DE) | 2005-03-10 | — | — | WO | disclosed |
| EP-0973774-B1 | 1,5-DIHYDRO-PYRAZOLO 3,4-D]-PYRIMIDINONE DERIVATIVES | BAYER AG (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020132754-A1 | Selective PDE 2 inhibitors as pharmaceuticals for improving perception | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132754-A1 | Selective PDE 2 inhibitors as pharmaceuticals for improving perception | PDE12, PDE2A, PDE4B | PDE2A 2/4885CCNE1 4565/4885CDK2 1900/4885 |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PDE12, PDE2A, PDE3A | PDE2A 2/4885CCNE1 1768/4885CDK2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.